Redx Pharma

#Crohn's disease #Gastrointestinal #Inflammatory Bowel Disease #Phase I trial #Redx Pharma

Phase I data supports pan-ROCK inhibitor for Crohn’s disease

Redx Pharma has shared additional results from an RXC008 Phase I clinical trial at Digestive Disease Week 2025, San Diego, CA.  RXC008 is a highly potent pan-Rho-associated coiled-coil kinase (pan-ROCK) inhibitor that was designed to be restricted to the gastrointestinal (GI) tract.   The Phase I… Read More

#News

Gastrointestinal tract
#Cancer #Clinical trials #Drug development #ESMO #Gastrointestinal #Redx Pharma #Wnt inhibition

Redx Pharma reports on zamaporvint cancer treatment trials 

Redx Pharma has announced data from all Phase II clinical trial modules of zamaporvint (RXC004), a potent, selective, orally-active Porcupine inhibitor in development for Wnt-ligand dependent, hard-to-treat gastrointestinal (GI) cancers.   These data, presented at the European Society for Medical Oncology Gastrointestinal Cancers (ESMO GI) Congress, were from… Read More

#Cancer Research #News